by
Raquel,
Vicente, E. (Esther),
Solano, B. (Beatriz),
Pérez-Silanes, S. (Silvia),
Aldana, I. (Ignacio),
Maddry, J.A. (Joseph A.),
Lenaerts, A.J. (Anne J.),
Franzblau, S.G. (Scott G.),
Cho, S.H. (Sang-Hyun),
Monge, A. (Antonio),
Goldman, R.C. (Robert C.)
Published 2013
“…Methods: Ketone and amide derivatives of quinoxaline 1,4-di-N-oxide were evaluated in in vitro and in vivo tests including: (i) activity against M. tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to
isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824.
…”
Get full text
info:eu-repo/semantics/article